MedTrace Logo

Role of PLA2G1B During HIV Infection

NCT04208711 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2021-02-08

No results posted yet for this study

Summary

The main objective of this study is to qualify and quantify, by microscopy techniques, CD4+ lymphocyte abnormalities during HIV infection in 7 patients who are naive to any ARV (antiretroviral ) treatment and secondarily to follow the kinetics of reversion of the observed abnormalities, as well as the evolution of the levels of PLA2G1B and its cofactor gp41 in 8 patients under ARV treatment

Conditions

  • HIV Infections

Interventions

OTHER

biological sample

whole blood sample

Sponsors & Collaborators

  • CIC 1417 Cochin-Pasteur

    collaborator OTHER

  • Diaccurate SAS

    lead INDUSTRY

Principal Investigators

  • Odile LAUNAY, MD, PHD · CIC 1417 Clinical Center Investigation - Cochin Hospital, AP-HP

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2022-03-31
Completion
2022-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04208711 on ClinicalTrials.gov